KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2025)

Amneal Pharmaceuticals has reported Total Current Liabilities over the past 9 years, most recently at $881.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $881.6 million for Q4 2025, down 21.96% from a year ago — trailing twelve months through Dec 2025 was $881.6 million (down 21.96% YoY), and the annual figure for FY2025 was $881.6 million, down 21.96%.
  • Total Current Liabilities for Q4 2025 was $881.6 million at Amneal Pharmaceuticals, up from $862.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for AMRX hit a ceiling of $1.1 billion in Q4 2024 and a floor of $602.0 million in Q1 2022.
  • Median Total Current Liabilities over the past 5 years was $826.2 million (2022), compared with a mean of $850.4 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 34.02% in 2021 and later soared 47.59% in 2022.
  • Amneal Pharmaceuticals' Total Current Liabilities stood at $677.2 million in 2021, then rose by 11.16% to $752.8 million in 2022, then grew by 12.46% to $846.6 million in 2023, then surged by 33.45% to $1.1 billion in 2024, then fell by 21.96% to $881.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $881.6 million (Q4 2025), $862.1 million (Q3 2025), and $1.1 billion (Q2 2025) per Business Quant data.